The prognostic significance of micrometastases in breast cancer: A SEER population-based analysis

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3378-3384

  Chen, Steven L ^a   Hoehne, Francesca M ^a   Giuliano, Armando E ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Lymph node; Micrometastasis; Prognosis; Staging

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIFFERENTIATION; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; SEER PROGRAM; SURVIVAL RATE;

EID: 36349035978     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9513-6     Document Type: Article

References (21)

1. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, et al. (Eds) AJCC Cancer Staging Manual 6th ed, 2002
2. De Mascarel I, MacGrogan G, Picot V, Mathoulin-Pelissier S. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002; 87:70-74
3. Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004; 239:828-840
4. Masuda N, Tamaki Y, Sakita I, et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription- polymerase chain reaction in breast cancer patients. Clin Cancer Res 2000; 6:4176-4185
5. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391-398
6. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 394-401
7. Van der Heiden-van der Loo M, Bezemer PD, Hennipman A, Siesling S, van Diest PJ, Bongers V, Peeters PH. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 2006; 32:710-714
8. Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006; 59:518-522
9. National Cancer Institute. Overview of the SEER Program. Available on the World Wide Web at http://www.seer.cancer.gov/about /. Accessed March 29, 2006
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 195; 53:457-481
11. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34:187-220
12. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Eng J Med 2005; 353:793-802
13. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006; 24:4270-4276
14. De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66:523-527
15. Colpaert C, Vermeulen P, Jeuris W, et al. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by features of the primary tumour. J Pathol 2001; 193:442-449
16. Millis RR, Springall R, Lee AH, Ryder K, Rytina ER, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002; 86:396-401
17. Kahn HJ, Hanna WM, Chapman JA, et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 2006; 12:291-293
18. Reed W, Bohler PJ, Sandstad B, Nesland JM. Occult metastases in axillary lymph nodes as a predictor of survival in node negative breast carcinoma with long-term follow-up. Breast J 2004; 10:174-180
19. Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG, McGuckin MA. Occult axillary lymph node metastases in breast cancer do matter: results of 10 year survival analysis. Am J Surg Pathol 2002; 26:1286-1295
20. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354:896-900
21. Cserni G, Bianchi S, Boecker W, Decker T, Lacerda M, Rank F, Wells CA. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 2004; 103:358-367